Drugs / Lyumjev
last change Jun 2026 re-read 2 minutes ago

Lyumjev

Developed for
type 1 diabetes mellitus
Investigated by
Eli Lilly and Company · Norwegian University of Science and Technology · St. Olavs Hospital

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (2) US (FDA) LYUMJEV 2021-08-13 – 2022-10-14 fda.gov
Approved US (FDA) LYUMJEV 2020-06-15 fda.gov

Trials 2 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05262387 Feb 2022 → Mar 2023 type 1 diabetes mellitus Eli Lilly and Company Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT06854861 Apr → Nov 2025 type 1 diabetes mellitus St. Olavs Hospital Suspended No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT06021158 Background Dec 2023 → Dec 2024 type 1 diabetes mellitus McGill University Health Centre/Research Institute of the McGill University Health Centre Unknown No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT06046417 Background Nov 2023 → Apr 2025 type 1 diabetes mellitus McGill University Health Centre/Research Institute of the McGill University Health Centre Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Lyumjev ClinicalTrials.gov intervention name — accepted as the source's own label NCT05262387
3

NCT06854861

NCT06021158

NCT06046417

Known as ultrarapid lispro insulin “We developed a novel automated insulin delivery (AID) system using ultrarapid lispro insulin (Lyumjev®), replacing carbohydrate counting with qualitative meal-size estimation...” PMID 42267693 Jun 2026
Route Subcutaneous “Administered SC.” NCT05262387